Marker Therapeutics, Inc.
MRKR· Nasdaq
MRKRMarker Therapeutics, Inc.
Released Mar 18, 2026, after the close
10-K filed Mar 18, 2026, 77 days after period end · 0001104659-26-031274
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.10M | $2.25M | $1.06M | $759.14K |
| Net Income | -$1.70M |
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
| -$3.84M |
| -$2.80M |
| -$3.86M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
